Alena Gros
@alena_grosvidal
ID: 4899313559
11-02-2016 21:17:02
43 Tweet
548 Followers
212 Following
📢 Great news! ESMO IOTECH has been officially accepted for indexing in Elsevier | Scopus.
On #WorldCancerDay and every day we work to understand how T cells recognize and kill cancer cells to develop new T-cell therapies Vall d’Hebron Institute of Oncology (VHIO) Fundación BBVA Asociación Española Contra el Cáncer Fundación Fero Ministerio de Ciencia, Innovación y Universidades Fundación ”la Caixa” La Marató de 3Cat
Excited to share that our manuscript exploring the immunogenicity of non-canonical HLA-I tumor peptides identified through proteogenomics can be found on biorxiv! Kudos to Maria Lozano-Rabella and the team Vall d’Hebron Institute of Oncology (VHIO) for all the work. biorxiv.org/content/10.110…
🗞 Recently published in Journal for ImmunoTherapy of Cancer! Alena Gros and Jara Palomero from VHIO report that "Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer” ➕ jitc.bmj.com/content/10/12/… #CAIMI #AGAUR
Our new study on Endometrial Cancer TILs was recently published in Journal for ImmunoTherapy of Cancer! Congrats to all the ITAG team Vall d’Hebron Institute of Oncology (VHIO) and collaborators, especially, to Jara Palomero for the work. Thanks to Fundación BBVA, @AGAUR, La Marató de 3Cat, Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades. jitc.bmj.com/content/10/12/…
Insightful commentary on the detection of cryptic peptides and their importance in cancer immune surveillance by Bernard A Fox and colleagues. Looking forward to see how the field evolves! aacrjournals.org/clincancerres/…
📣 Inscríbete ahora al próximo #VHIOTalks‼️ 🔹 Terapia celular en tumores sólidos 🗣 Con @ElenaGarralda, Alena Gros, Enric Barba Ibáñez y Pere Estupinyà. 🗓 13 de septiembre ⏰ 18 h 📍 Artchimboldi Inscríbete aquí 👉bit.ly/Terapiacelular… #VHIOTalks
📣 Thrilled to announce the 1st VHIO Fundación BBVA Symposium in Cell-based Therapies in Oncology with a unique list of speakers including Dirk Busch, Luca Gattinoni, John Haanen, Robbie Majzner, and more! 📍Barcelona,29th-30th Nov 🗓 Apply by Oct 7th vhio.net/vhio-bbva-foun…
We are inviting submissions for our Special Issue on Developments in Cell Therapy ESMO IOTECH . Submission deadline: 8 March 2024. Find out more and submit your manuscript ➡️ spkl.io/60154sUYl ESMO IOTECH
FDA approves IOVANCE's TIL therapy AMTAGVI for advanced melanoma. Congrats to all the Iovance Biotherapeutics team as well to Steven A. Rosenberg and the @NCI_CCR_SB for this fantastic achievement. #Celltherapy #Melanoma ir.iovance.com/news-releases/…
An honor to speak at Keystone Symposia in Whistler, CA organized by @JimAllisonPhD @PamSharmaMDPhD and @ Toni Ribas. Also went to the @NCI_CCR_SB to share my group's work and visit my former supervisor and mentor Steven A. Rosenberg. A week full of fantastic science and friends!
The registrational enabling Spearhead-1 study shows that afami-cel, an engineered T cell targeting MAGEA4, has promising efficacy in synovial sarcoma and MRCLS paving the way for T cell therapy in solid tumors. Memorial Sloan Kettering Cancer Center MSK Department of Medicine Sarcoma Service at Memorial Sloan Kettering sciencedirect.com/science/articl…
Excited to share that our paper is now out in Nature Communications! We explore how CAR affinity influences CAR-T cell sensitivity to PD1/PD-L1 inhibition. Huge congrats to Irene Andreu and Alba Rodríguez for their exceptional work! IDIBAPS Hospital Clínic doi.org/10.1038/s41467…